Neutral
Last updated: 2026-05-21 19:46:27 ET
The injection is different than Zepbound and Foundayo.
The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from existing injections and pills.
People who got the injection, retatrutide, lost 28 percent of their body weight on average after 80 weeks, Eli Lilly said.
Canadian AI lab Cohere made waves recently by announcing a merger with German AI startup Aleph Alpha, but now it has even more in store for enterprise...
Less than a week after completing the largest tech IPO of 2026, Cerebras Systems is making its most aggressive play yet to dominate the fast-growing A...
Mindy Kaling, 46, says becoming a mom changed why she wanted to lose weight
Thomas Massie, the Kentucky Republican congressman locked in a heated primary battle with a Trump-backed challenger, is fundraising from anti-war, Mus...
Emerging research shows there are ‘super-responders’ to GLP-1 drugs, and others who don’t respond at all.
The weight loss pill had a strong U.S. launch this year, and Novo believes that will be replicated in other markets around the world.
Earlier this week, Eli Lilly reported detailed late-phase obesity trial results showing long-term weight maintenance with injectable Zepbound and oral...
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE